Adenoviral disease presentation and responses to each VST infusion
| . | Total . | Donor-derived VST . | Third-party VST . |
|---|---|---|---|
| No. of patients with an indication for VST | 30 | 7 | 23 |
| Viremia | 9 | 3 | 6 |
| Invasive disease | 6 | 0 | 6 |
| Viremia + invasive disease | 15 | 4 | 11 |
| ADV infection (viremia) presentation before first VST infusion | |||
| Median no. of adenovirus copies per mL before first VST infusion (range) | 40 977 (0-450 000 000) | 5184 (0-191 965) | 116 599 (0-450 000 000) |
| Site of invasive disease | |||
| Diarrhea/enteritis | 18 | 3 | 15 |
| Respiratory tract | 5 | 2 | 3 |
| Antiviral therapy before first VST infusion | |||
| Cidofovir | 12 | 1 | 11 |
| Brincidofovir | 8 | 3 | 5 |
| Cidofovir and brincidofovir | 5 | 0 | 5 |
| None | 5 | 2 | 3 |
| Antiviral therapy at the time of first VST infusion | |||
| Cidofovir | 7 | 1 | 6 |
| Brincidofovir | 4 | 0 | 4 |
| Acyclovir/valacyclovir | 9 | 3 | 6 |
| Ganciclovir | 3 | 1 | 2 |
| None | 9 | 2 | 7 |
| Adenovirus best response to VSTs in evaluable patients (%) | |||
| CR | 54 | 86 | 42 |
| PR | 27 | 14 | 32 |
| CR+PR | 81 | 100 | 74 |
| NR | 19 | 0 | 26 |
| Median No. of evaluable VST infusions (range) | 1 (1-2) | 1 (1-3) | |
| Infusion reaction | 0 | 0 | 0 |
| aGVHD within 30 days of VST infusion | 1 | 0 | 1 |
| . | Total . | Donor-derived VST . | Third-party VST . |
|---|---|---|---|
| No. of patients with an indication for VST | 30 | 7 | 23 |
| Viremia | 9 | 3 | 6 |
| Invasive disease | 6 | 0 | 6 |
| Viremia + invasive disease | 15 | 4 | 11 |
| ADV infection (viremia) presentation before first VST infusion | |||
| Median no. of adenovirus copies per mL before first VST infusion (range) | 40 977 (0-450 000 000) | 5184 (0-191 965) | 116 599 (0-450 000 000) |
| Site of invasive disease | |||
| Diarrhea/enteritis | 18 | 3 | 15 |
| Respiratory tract | 5 | 2 | 3 |
| Antiviral therapy before first VST infusion | |||
| Cidofovir | 12 | 1 | 11 |
| Brincidofovir | 8 | 3 | 5 |
| Cidofovir and brincidofovir | 5 | 0 | 5 |
| None | 5 | 2 | 3 |
| Antiviral therapy at the time of first VST infusion | |||
| Cidofovir | 7 | 1 | 6 |
| Brincidofovir | 4 | 0 | 4 |
| Acyclovir/valacyclovir | 9 | 3 | 6 |
| Ganciclovir | 3 | 1 | 2 |
| None | 9 | 2 | 7 |
| Adenovirus best response to VSTs in evaluable patients (%) | |||
| CR | 54 | 86 | 42 |
| PR | 27 | 14 | 32 |
| CR+PR | 81 | 100 | 74 |
| NR | 19 | 0 | 26 |
| Median No. of evaluable VST infusions (range) | 1 (1-2) | 1 (1-3) | |
| Infusion reaction | 0 | 0 | 0 |
| aGVHD within 30 days of VST infusion | 1 | 0 | 1 |
aGVHD, acute graft-versus-host disease; NR, no response.